Diagnostic Evaluation of Poor Memory in a 50-Year-Old Patient

Introduction to Cognitive Impairment

The American College of Radiology recommends using MRI over CT for detecting vascular lesions in patients with cognitive impairment 1
A structured diagnostic evaluation is necessary for a 50-year-old patient with poor memory, including validated cognitive screening, corroborated informant history, comprehensive laboratory testing, and brain MRI to exclude reversible causes 1

The Montreal Cognitive Assessment (MoCA) is the preferred primary screening instrument for mild cognitive impairment, as recommended by the Alzheimer's Association 2
Alternative rapid screening options include the Mini-Cog, Memory Impairment Screen plus Clock Drawing Test, or the four-item MoCA 2
The MMSE lacks sensitivity for mild cognitive impairment or early dementia, according to the Alzheimer's Association 2
Interview a reliable informant separately from the patient using validated questionnaires such as the AD8 or IQCODE to obtain corroborated history 1, 2

Mandatory first-line tests include Complete Blood Count (CBC), Comprehensive Metabolic Panel, Thyroid-Stimulating Hormone (TSH), Vitamin B12 and folate levels, liver function tests, Hemoglobin A1c (HbA1c), and lipid panel 1
Brain MRI is the preferred initial imaging modality to evaluate for stroke, white matter disease, atrophy patterns, hydrocephalus, subdural hematoma, tumors, and space-occupying lesions 1

Determine whether episodic memory is the primary impaired domain, as this is most commonly seen in patients who progress to Alzheimer's disease dementia 3, 4
Assess whether impairments in other cognitive domains predominate, such as executive function, attention, language, or visuospatial abilities 3, 4
Screen for conditions associated with cognitive disorders, including history of stroke or TIA, late-onset depressive disorder, untreated sleep apnea, unstable metabolic or cardiovascular morbidity, recent episode of delirium, and recent head injury 2

Obtain serial cognitive assessments to document progressive decline over time, which strengthens diagnostic accuracy 3, 4
Schedule follow-up visits every 6-12 months to track disease progression using a multi-dimensional approach monitoring cognition, functional autonomy, and behavioral symptoms 1
Consider advanced testing, such as lumbar puncture with CSF analysis for Alzheimer's biomarkers or evaluation for autoimmune/infectious/paraneoplastic causes, in selected cases with early-onset presentation or rapidly progressive course 1